Obesity Management Market Information, by Prescription Weight-loss Medication Orlistat (Xenical), Phentermine (Adipex) and others; by Surgery; by Lifestyle changes (Dietary Changes, Exercise, and others)
Obesity management Market is growing moderately. Changing lifestyle and unhealthy eating habits are leading to the problem of obesity. The population of obese people are increasing globally. Obesity leads to various diseases such as diabetes, hypertension, heart diseases and many others. Drugs manufacturers investing their money in R&D to develop effective anti-obesity drugs. Earlier obesity was considered as problem of high income countries but now it's shifting towards low-middle income countries. Healthcare solution providers are developing new and innovative solutions for healthcare sector. Hospitals also providing different surgery options according to medical history and condition of the patient. Obesity management Market is expected to grow at the average CAGR of 8.4% during 2015-2022. Obesity management Market is expected to reach US$ 6.2 billion by 2022 from US$ 4.17 billion in 2015. However, several side effects of drugs, regulatory issues and high cost are the major restraints for the market.
Obesity Management Market has been segmented on the basis of Prescription weight-loss medication which comprise orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), buproprion and naltrexone (Contrave), and liraglutide (Saxenda), and others. On the basis of Surgery it segmented into Gastric bypass surgery, Laparoscopic adjustable gastric banding (LAGB), Biliopancreatic diversion with duodenal switch, and others. On the basis of lifestyle changes it is segmented into Dietary changes, Exercise, and others.
Considering the global scenario of the market, North America region is believed to be the largest market for Obesity management. Moreover the European market is also growing and second largest market for Obesity management. On the other hand, Asia-Pacific market is expected to grow at significant rate in the Obesity management during the forecasted period. Rest of the World is likely to have a limited but steady growth in the market.
Some of the key players in this market are: Pfizer Inc. (US), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (UK), AstraZeneca (UK), Herbalife Ltd. (U.S.), Apollo Endosurgery (U.S.), Ethicon, Inc. (U.S.)
The report for Obesity Management Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.